Article

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort

2023-05-08

Abstract excerpt

<title>Abstract</title> <p>Time-limited treatment strategies in first line treatment of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) were comprehensively explored. Thirty-four previously untreated, young fit CLL/SLL patients who initiated iFCR regimen between January 2019 and Match 2021 were included in our cohort. iFCR were administered every 28-day cycle, with a maximum of six cycles. Patie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b712144c-1bca-5946-8255-0ccabe7c71d7
DOI: 10.21203/rs.3.rs-2888639/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohortDOI 10.21203/rs.3.rs-2888639/v1Read

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudySemantic proximity Read

Chronic lymphocytic leukemia treatment algorithm 2022.Semantic proximity Read

Ibrutinib versus bendamustine plus rituximab for first-line treatment of older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research studySemantic proximity Read

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.Semantic proximity Read

Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.Semantic proximity Read

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity Read

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.Semantic proximity Read

Chronic lymphocytic leukemia in a young population.Semantic proximity Read

Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.Semantic proximity Read

Chronic lymphocytic leukemia: a clinical review including Korean cohorts.Semantic proximity Read